Biosimilar Bevacizumab (Stivant®) Shows Promise in Treating Retinopathy of Prematurity: A Pilot study Review
Retinopathy of Prematurity (ROP) remains a leading cause of childhood blindness globally. Bevacizumab (avastin®) has become a cornerstone of ROP treatment, but access and cost can be significant hurdles. Recently, biosimilar versions like Stivant® are emerging as potential alternatives. This article dives into a recent pilot study comparing Stivant® to Avastin® in preterm infants with ROP, offering insights for clinicians and those involved in neonatal care.
Understanding the Challenge: ROP and Bevacizumab
ROP develops in premature infants due to abnormal blood vessel advancement in the retina.if left untreated, it can lead to vision loss. Bevacizumab,a vascular endothelial growth factor (VEGF) inhibitor,helps stop the progression of ROP by reducing abnormal blood vessel growth. However, manufacturing variations and differing regulatory pathways across regions can impact availability.
the study: A Head-to-Head comparison
researchers conducted a clinical trial focusing on preterm infants diagnosed with bilateral prethreshold type 1 ROP. The study employed a contralateral design – meaning each infant received Stivant® in one eye and Avastin® in the other. this approach minimizes individual patient variability, providing a more direct comparison.
Here’s a breakdown of the study design:
* Participants: 54 preterm infants.
* Intervention: Bilateral intravitreal injections - Stivant® (0.625 mg/0.025 mL) in the right eye and Avastin® in the left.
* Follow-up: Weekly for 4 weeks, then bi-weekly until complete retinal vascularization.
* Primary Outcome: The number of eyes achieving complete vascularization without needing laser photocoagulation (a rescue treatment).
* Secondary Outcome: Time to complete vascularization.
Key Findings: Comparable Efficacy and Safety
The results were encouraging. The study found no statistically significant difference in the time to complete retinal vascularization between the stivant® and Avastin® groups (25.55 ± 12.66 weeks vs. 25.46 ± 12.45 weeks, P* = .59).
Furthermore:
* Plus Disease Regression: Regression of ”plus disease” (venous dilation and arteriolar tortuosity) occurred at a similar rate in both groups (11.3%, *P = 1). This suggests Stivant® effectively addresses ROP activity.
* Safety Profile: Crucially, no local or systemic drug-related adverse events were observed in either group. This is vital when considering treatment options for vulnerable newborns.
Why These Findings Matter to You
As a healthcare professional, you need reliable data to make informed decisions. This study provides preliminary evidence suggesting Stivant® is a viable alternative to Avastin® for treating prethreshold type 1 ROP. The comparable efficacy and safety profile could potentially:
* Increase Access: Biosimilars are frequently enough more affordable,potentially expanding treatment access for more infants.
* Reduce Costs: Lower drug costs can alleviate financial burdens on healthcare systems and families.
* Offer Treatment Flexibility: Having multiple options allows for tailored treatment plans based on individual patient needs and regional availability.
Limitations and Future Directions
The study authors acknowledge limitations, primarily the relatively small sample size. They rightly classify this as a pilot study – a crucial first step.
Here’s what needs to happen next:
* Larger randomized Controlled Trials: Larger studies are essential to confirm these findings and establish definitive evidence of non-inferiority.
* Long-Term Follow-up: Monitoring long-term visual outcomes is critical to fully assess the impact of Stivant® treatment.
* Exploration of Biomarkers: Identifying biomarkers that predict treatment response could personalize ROP management.
The Bottom Line
This pilot study offers a promising glimpse into the potential of biosimilar bevacizumab (Stivant®) in the fight against ROP. while further research is needed, the initial findings suggest it’s a safe and effective alternative to Avastin®. You can stay informed about future developments and contribute to improved outcomes for preterm infants at risk of vision loss.
REFERENCE:
- Mojtaba A, Z